| Previous Close | 24.02 |
| Open | 24.07 |
| Bid | 21.86 x 1300 |
| Ask | 25.88 x 1000 |
| Day's Range | 23.90 - 23.90 |
| 52 Week Range | 22.61 - 25.92 |
| Volume | 2,691 |
| Avg. Volume | 1,737 |
| Net Assets | 24.56M |
| NAV | 24.10 |
| PE Ratio (TTM) | N/A |
| Yield | 1.12% |
| YTD Return | 2.23% |
| Beta (3Y Monthly) | 5.17 |
| Expense Ratio (net) | 0.75% |
| Inception Date | 2006-09-18 |
Montrouge, France, February 4, 2019 DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 Novel immunotherapy based on Viaskin technology.
Montrouge, France, February 1, 2019 DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference DBV Technologies (Euronext: DBV -.
DBV's Chief Scientific Officer (CSO), Dr. Hugh Sampson, will also assume the role of interim Chief Medical Officer (CMO) effective today. Dr. Sampson succeeds Dr. Lucia Septien-Velez, who has decided to leave to pursue other opportunities.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that after discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut in children four to 11 years of age has been voluntarily withdrawn. DBV is currently working closely with the agency to resubmit the application for Viaskin Peanut as quickly as possible.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that an oral abstract evaluating differences in the immune profile of healthy human skin across different body areas was presented by Dr. Ester Del Duca, Icahn School of Medicine at Mount Sinai, at the 3rd Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria, December 12-15, 2018.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that three oral abstracts supporting the therapeutic potential of Viaskin Peanut were presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2018 Annual Scientific Meeting in Seattle, Washington, November 15-19, 2018. The presentations included additional analyses from PEPITES, a pivotal Phase III efficacy and safety study of Viaskin Peanut in children ages four to 11.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has unanimously appointed Daniel Tassé as its Chief Executive Officer (CEO) effective November 29, 2018. Dr. Pierre-Henri Benhamou, who co-founded the Company in 2002, will retire as CEO and serve as Non-Executive Chairman of the Board.
Montrouge, France, November 9, 2018 DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the.
Montrouge, France, October 30, 2018 DBV Technologies Reports September 30, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock.